Mark C. McKenna's Net Worth
$14.7 Million
Who is Mark C. McKenna?
Mark C. McKenna has an estimated net worth of $14.7 Million. This is based on reported shares across multiple companies, which include Bausch Health Companies Inc., Prometheus Biosciences, Inc., Apogee Therapeutics, Inc., Spyre Therapeutics, Inc., Helix Acquisition Corp. II, Perceptive Capital Solutions Corp, and NewAmsterdam Pharma Co N.V..
SEC CIK
Mark C. McKenna's CIK is 0001749623
Past Insider Trading and Trends
2023 was Mark C. McKenna's most active year for acquiring shares with 11 total transactions. Mark C. McKenna's most active month to acquire stocks was the month of January. 2023 was Mark C. McKenna's most active year for disposing of shares, totalling 25 transactions. Mark C. McKenna's most active month to dispose stocks was the month of May. 2023 saw Mark C. McKenna paying a total of $757,836.30 for 397,531 shares, this is the most they've acquired in one year. In 2023 Mark C. McKenna cashed out on 2,578,076 shares for a total of $14,988,430.60, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Bausch Health Companies Inc. (BHC) Snapshot price: $6.1229
President, Salix
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -34.17% | -10.77K |
$21.83 | -$235,220.91 | 20.76K |
Aug 19
| |||
Form 4
| -5.72% | -1.91K |
$23.82 | -$45,567.66 | 31.53K |
Jun 24
| |||
Form 4
| -2.18% | -746.00 |
$23.51 | -$17,538.46 | 33.44K |
May 6
| |||
Form 4
| -2.77% | -974.00 |
$23.56 | -$22,947.44 | 34.19K |
Mar 8
| |||
Form 4
| +76.33% | 15.22K |
—
|
—
| 35.16K |
Feb 27
| |||
Form 4
| -5.63% | -1.19K |
$21.25 | -$25,287.50 | 19.94K |
Jan 8
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Prometheus Biosciences, Inc. No price found
Chairman, President and CEO
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -100.00% | -178.10K |
—
|
—
|
0
|
Jun 16
| |||
Form 4
| +52.55% | 122.53K |
$2.30 | $355,336.30 | 355.71K |
Jun 2
| |||
Form 4
|
—
|
0
|
$59.52 | -$2,831,000.00 | 55.14K |
Scheduled
|
Mar 15
| ||
Form 4
|
—
|
0
|
$64.42 | -$1,374,678.60 | 55.14K |
Scheduled
|
Mar 1 - Mar 3
| ||
Form 4
|
—
|
0
|
$62.11 | -$7,478,002.00 | 55.14K |
Scheduled
|
Feb 15 - Feb 17
| ||
Form 4
|
—
|
0
|
$60.95 | -$2,902,250.00 | 55.14K |
Scheduled
|
Jan 17
| ||
Form 4
| +205.83% | 37.11K |
—
|
—
| 55.14K |
Dec 9
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 20
| |||
Form 4
|
∞
| 15.4K |
$2.90 | $44,660.00 | 15.4K |
Dec 1
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Nov 14
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Apogee Therapeutics, Inc. (APGE) Snapshot price: $47.25
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 5
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Aug 17
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Spyre Therapeutics, Inc. (AGLE) No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 1
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Helix Acquisition Corp. II No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||